Breast cancer
Theragnostic testing – choosing the right therapy in mTNBC

Martina (54 years old)

Martina is 54 years old and used to work as a consultant. She was diagnosed with early stage TNBC at the age of 51. Unfortunately, tumour progression was detected a week ago.

Assessment summary

  • Postmenopausal
  • No relevant family history
  • Genetic testing: no gBRCA1/2 pathogenic variants
  • No relevant comorbidities
  • ECOG PS: 0
  • Medical history
    • 3 years ago, diagnosed with early stage TNBC (cT3N2M0, right side)
      • Neoadjuvant chemotherapy: anthracycline-taxane + carboplatin
      • Mastectomy (right side) and ALND (no pCR: ypT1 ypN1)
      • Post-mastectomy radiation therapy
      • Post-neoadjuvant capecitabine (6 cycles)
    • 1 year ago, staging including CT scan of chest/abdomen and bone scan: 2 liver lesions
      • Biopsy (liver lesion)
        • Breast cancer, ER 0%, PgR 0%, HER2 IHC 0, G3
        • PD-L1 status: CPS 3, IC score 4%
      • Therapy with atezolizumab + nab-paclitaxel for 6 months
  • Today, CT scan shows progression of the liver lesions and 2 new lung lesions

Which of the following treatment options would you choose for this patient?